MINNEAPOLIS--(BUSINESS WIRE)--Cell Culture Company (C3), a biopharmaceutical developer and manufacturer, announced today it has entered into an agreement with a China-based joint venture to produce a clinical-grade antibody-based therapeutic vaccine targeting pancreatic cancer.  Read More...

MINNEAPOLIS – Jan. 20, 2016 – Biovest International Inc. announced that it will spin off its instrument and contract manufacturing offerings into a single wholly-owned subsidiary named "Cell Culture Company, LLC." Cell Culture Company will supply automated single-use perfusion bioreactor systems and custom mammalian cell and protein manufacturing services to the diagnostic, therapeutic, and animal healthcare industries. Read More...